Vanda Pharma: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Vanda Pharma (NASDAQ:VNDA) reported its Q3 earnings, missing estimated earnings by 100.0% with an EPS of $0.0 versus an estimate of $-0.04. Revenue was down $26.50 million from the same period last year. Last quarter, the company beat on EPS by $0.16, which was followed by a 8.05% drop in the share price the next day.
November 08, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vanda Pharma's Q3 earnings missed estimates, and revenue was down from last year. The previous quarter's EPS beat led to a share price drop.
Vanda Pharma's earnings miss and revenue drop indicate a weaker financial performance, which could negatively impact investor sentiment and lead to a drop in the share price. The previous quarter's share price reaction to an EPS beat suggests that the market is sensitive to Vanda Pharma's earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100